Kinase inhibitors have limited success in cancer treatment because tumors circumvent their
action. Using a quantitative proteomics approach, we assessed kinome activity in response …

Approximately 30% of triple-negative breast cancers (TNBCs) exhibit functional loss of the
RB tumor suppressor, suggesting a target for precision intervention. Here, we use drug …

Abstract The RAS–RAF–MEK–ERK pathway is the most well-studied of the MAPK cascades
and is critical for cell proliferation, differentiation, and survival. Abnormalities in regulation …

Abstract The RAS/RAF/MEK pathway is activated in more than 30% of human cancers, most
commonly via mutation in the K-ras oncogene and also via mutations in BRAF. Several …

Alterations of signal transduction pathways leading to uncontrolled cellular proliferation,
survival, invasion, and metastases are hallmarks of the carcinogenic process. The …

Mammalian target of rapamycin (mTOR) is a component of a signaling pathway
(PTEN/PI3K/AKT) that is frequently dysregulated in cancer. However, its precise relationship …

Triple‐negative breast cancers (TNBC s) are known to be intrinsically resistant to inhibitors
for epidermal growth factor receptor (EGFR). Until now, clinical trials for TNBC s using EGFR …

Dysregulation of the PI3K-AKT-mTOR signaling network is a prominent feature of breast
cancers. However, clinical responses to drugs targeting this pathway have been modest …

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that does not
respond to endocrine therapy or human epidermal growth factor receptor 2 (HER2)–targeted …

Mitogen-activated protein kinase (MAPK) pathway dysregulation is implicated in> 30% of all
cancers, rationalizing the development of RAF, MEK and ERK inhibitors. While BRAF and …